Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 6

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---

     (4,779)
  
    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 
     20,922  
     35,848 
  
    CASH AND CASH EQUIVALENTS AT END OF PERIOD 
    $33,374  
    $31,069 

    SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: 

    Cash paid for income taxes 
    $-  
    $- 
  
    Cash paid for interest expense 
    $-  
    $523 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

5

INMUNE BIO INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND DESCRIPTION
OF BUSINESS

INmune Bio Inc. (the “Company” or
“INmune Bio”) was organized in the State of Nevada on September 25, 2015 and is a clinical stage biotechnology pharmaceutical
company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning
normally and contributing to the patient’s disease. INmune Bio has three product platforms. The DN-TNF product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of
many diseases and was used for its Alzheimer’s clinical trial (“XPro”). The CORDStrom product platform is a pooled,
human umbilical cord mesenchymal stem cell product currently being developed to treat recessive dystrophic epidermolysis bullosa (“RDEB”).
The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual
disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide
variety of hematologic malignancies, solid tumors and chronic inflammation.

NOTE 2 – GOING CONCERN 

These unaudited condensed consolidated financial
statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business.

The Company has incurred significant losses and
negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant